Literature DB >> 6925459

Immune reaction of tumor-bearing mice to Propionibacterium acnes and the antitumor effect of the bacteria.

V Silobrcic, G Fredrickson, R Sedlacek, H D Suit, G Wolberg.   

Abstract

The relationship between immunological reaction to Propionibacterium acnes (PA) and the antitumor effect of the injected bacterium was investigated. The aim was to determine whether the strength of the immune reaction to the bacterium can be used to predict its antitumor effectiveness. C3Hf/Sed mice received SC injections (right thigh) of viable cells of a methylcholanthrene-induced fibrosarcoma. When the tumor grew to 5 mm, the hosts received 350 micrograms PA IV as the antitumor treatment. Cellular immunity (footpad test) to PA was assayed in one group of these mice 14 days later, and in the other anti-PA agglutinins were determined 28 days later. The PA injection cured 22 of 58 mice in the first, and 20 of 46 mice in the second group. Footpad reaction and agglutinin titers to PA in cured mice were not statistically different from those in mice eventually killed by the tumor. Therefore, the strength of the immune reaction to PA in tumor-bearing mice could not be used to predict the antitumor effectiveness of the bacterium.

Entities:  

Mesh:

Year:  1982        PMID: 6925459     DOI: 10.1007/bf00199425

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

1.  Antibody to Corynebacterium parvum in normal human and animal sera.

Authors:  G Wolberg; G S Duncan; C Adlam; J K Whisnant
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

Review 2.  Antitumor activity of Corynebacterium parvum.

Authors:  L Milas; M T Scott
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

3.  Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice.

Authors:  M F Woodruff; W H McBride; N Dunbar
Journal:  Clin Exp Immunol       Date:  1974-07       Impact factor: 4.330

4.  Immunologic status of host and response of a methylcholanthrene-induced sarcoma to local x-irradiation.

Authors:  H D Suit; A Kastelan
Journal:  Cancer       Date:  1970-07       Impact factor: 6.860

5.  Detection of cellular immunity to tumor-associated antigen(s) in mice by the macrophage spreading inhibition test.

Authors:  I Svoboda; R Măzuran; S Rabatić
Journal:  Int J Cancer       Date:  1977-03-15       Impact factor: 7.396

6.  Failure of Corynebacterium parvum presensitization to modify the antitumor effects of systemic and local therapeutic injections of C. parvum in mice.

Authors:  M T Scott
Journal:  J Natl Cancer Inst       Date:  1976-03       Impact factor: 13.506

Review 7.  Active non-specific immunotherapy of experimental tumours.

Authors:  V Silobrcić
Journal:  Folia Biol (Praha)       Date:  1980       Impact factor: 0.906

8.  Effect of Corynebacterium parvum on the response to irradiation of a C3H fibrosarcoma.

Authors:  H D Suit; R Sedlacek; M Wagner; L Orsi; V Silobrcic; K J Rothman
Journal:  Cancer Res       Date:  1976-04       Impact factor: 12.701

9.  A simple and inexpensive method for maintaining a defined flora mouse colony.

Authors:  R S Sedlacek; K A Mason
Journal:  Lab Anim Sci       Date:  1977-10

10.  Immunity to transplantable carcinogen-induced fibrosarcomas in B2/B2 chickens. III. Tumor growth inhibition by local delayed hypersensitivity reactions to unrelated antigens.

Authors:  M A Palladino; G J Thorbecke
Journal:  Eur J Immunol       Date:  1978-04       Impact factor: 5.532

View more
  2 in total

1.  Prominent IL-12 production and tumor reduction in athymic nude mice after Toxoplasma gondii lysate antigen treatment.

Authors:  Kyoung-Ho Pyo; Bong-Kwang Jung; Chun-Feng Xin; You-Won Lee; Jong-Yil Chai; Eun-Hee Shin
Journal:  Korean J Parasitol       Date:  2014-12-23       Impact factor: 1.341

2.  Antitumor effect of normal intestinal microflora on Ehrlich ascites tumor.

Authors:  K Sakamoto; K Konishi
Journal:  Jpn J Cancer Res       Date:  1988-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.